RecruitingEarly Phase 1NCT07253259
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
Sponsor
Grit Biotechnology
Enrollment
36 participants
Start Date
Dec 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called GT729 Injection for people with cgvhd. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALGT729 Injection
GT729 Injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07253259
Related Trials
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
NCT066637223 locations
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
NCT062446281 location
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT0591951132 locations
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
NCT072460311 location
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
NCT069201991 location